Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations

v3.3.0.814
Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Revenue:        
Lymphoseek sales revenue $ 2,952,522 $ 1,101,071 $ 6,751,492 $ 2,773,959
Lymphoseek license revenue 550,000 300,000 883,333 300,000
Grant and other revenue 476,755 848,999 1,320,816 1,002,605
Total revenue 3,979,277 2,250,070 8,955,641 4,076,564
Cost of goods sold 457,590 807,880 1,239,377 1,271,598
Gross profit 3,521,687 1,442,190 7,716,264 2,804,966
Operating expenses:        
Research and development 3,902,155 4,158,085 10,180,517 14,496,977
Selling, general and administrative 3,942,609 2,646,591 13,485,576 11,465,076
Total operating expenses 7,844,764 6,804,676 23,666,093 25,962,053
Loss from operations (4,323,077) (5,362,486) (15,949,829) (23,157,087)
Other income (expense):        
Interest expense, net (2,148,369) (918,026) (4,690,686) (2,764,122)
Equity in loss of R-NAV, LLC (26,785) (262,198) (295,217) (262,198)
Change in fair value of financial instruments (1,577,275) (409,650) (1,702,902) (109,499)
Loss on extinguishment of debt     (2,440,714) (2,610,196)
Other, net 4,402 53,464 26,100 41,419
Total other income (expense), net (3,748,027) (1,536,410) (9,103,419) (5,704,596)
Net loss (8,071,104) (6,898,896) (25,053,248) (28,861,683)
Less loss attributable to noncontrolling interest (340)   (681)  
Deemed dividend on beneficial conversion feature of MT Preferred Stock     (46,000)  
Net loss attributable to common stockholders $ (8,070,764) $ (6,898,896) $ (25,098,567) $ (28,861,683)
Loss per common share (basic and diluted) $ (0.05) $ (0.05) $ (0.17) $ (0.19)
Weighted average shares outstanding (basic and diluted) 150,186,131 150,169,712 150,030,638 148,344,064